Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Delayed and sustained minimal residual disease response predictsfavorable outcomes in newly diagnosed multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

LQLugui Qiu

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows prolonged MRD duration improves progression-free survival in multiple myeloma, indicating better long-term outcomes.

Key Points

  • To analyze the clinical relevance of minimal residual disease (MRD) response timing and duration in multiple myeloma patients.
  • Retrospective analysis of 1,048 newly diagnosed multiple myeloma patients
  • Assessment of 5,406 MRD evaluations
  • Evaluation of progression-free and overall survival related to MRD response timing and duration
  • Longer time to best MRD response (>6 months) associated with improved progression-free and overall survival
  • Prolonged MRD duration (≥36 months) predicts favorable outcomes regardless of MRD negativity
  • Integration of response timing and duration reveals a 'Late + Long' MRD pattern associated with best prognosis

Cite This Study

Lugui Qiu (2025) studied this question.

synapsesocial.com/papers/69362f5d4fa91c937236dbffhttps://doi.org/10.1182/blood-2025-7536
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Late and Durable Minimal Residual Disease Response Predicts Favorable Outcomes in Newly Diagnosed Multiple Myeloma2026
  2. 2Prognostic significance of dynamic minimal residual disease trajectories in newly diagnosed multiple myeloma2026
  3. 3Real-world prognostic significance of attaining minimal residual disease negativity in newly diagnosed multiple myeloma2024 · 14 citations
  4. 4Sustained MRD Negative for 4 Years Is a Significant Marker of Prognosis in Patients with High-Risk Multiple Myeloma2026
  5. 5Minimal residual disease dynamics in newly diagnosed multiple myeloma and impact on progression-free survival: A cohort study.2026